Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.33 - $10.44 $205,714 - $6.51 Million
623,376 Added 207.83%
923,314 $369,000
Q3 2022

Nov 14, 2022

BUY
$0.92 - $11.16 $137,527 - $1.67 Million
149,486 Added 99.36%
299,938 $255,000
Q2 2022

Aug 15, 2022

SELL
$1.02 - $1.83 $420,536 - $754,492
-412,291 Reduced 73.26%
150,452 $175,000
Q1 2022

May 16, 2022

BUY
$1.06 - $2.1 $356,533 - $706,339
336,352 Added 148.57%
562,743 $793,000
Q4 2021

Feb 14, 2022

SELL
$2.05 - $3.2 $1.47 Million - $2.29 Million
-717,120 Reduced 76.01%
226,391 $464,000
Q3 2021

Nov 15, 2021

BUY
$2.54 - $4.07 $278,178 - $445,742
109,519 Added 13.13%
943,511 $2.91 Million
Q2 2021

Aug 16, 2021

SELL
$2.57 - $4.85 $18,532 - $34,973
-7,211 Reduced 0.86%
833,992 $3.39 Million
Q1 2021

May 17, 2021

BUY
$1.9 - $2.82 $623,906 - $926,009
328,372 Added 64.03%
841,203 $2.08 Million
Q4 2020

Feb 16, 2021

BUY
$1.15 - $2.4 $562,031 - $1.17 Million
488,723 Added 2027.22%
512,831 $1.09 Million
Q3 2020

Nov 16, 2020

SELL
$1.11 - $1.68 $9,632 - $14,579
-8,678 Reduced 26.47%
24,108 $29,000
Q2 2020

Aug 14, 2020

BUY
$1.69 - $4.2 $55,408 - $137,701
32,786 New
32,786 $56,000
Q4 2019

Feb 14, 2020

SELL
$0.86 - $1.44 $168,226 - $281,681
-195,612 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$1.21 - $1.59 $186,831 - $245,505
154,406 Added 374.72%
195,612 $237,000
Q2 2019

Aug 14, 2019

SELL
$1.25 - $3.14 $49,310 - $123,866
-39,448 Reduced 48.91%
41,206 $62,000
Q1 2019

May 15, 2019

SELL
$2.79 - $4.09 $1.28 Million - $1.88 Million
-459,266 Reduced 85.06%
80,654 $239,000
Q4 2018

Feb 14, 2019

BUY
$3.23 - $7.01 $1.71 Million - $3.71 Million
528,829 Added 4768.09%
539,920 $1.81 Million
Q3 2018

Nov 14, 2018

BUY
$6.86 - $9.97 $76,084 - $110,577
11,091 New
11,091 $80,000

Others Institutions Holding VSTM

About Verastem, Inc.


  • Ticker VSTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 210,000,000
  • Market Cap $838M
  • Description
  • Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...
More about VSTM
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.